Panobinostat: Difference between revisions

	WikiDoc Resources for Panobinostat
Articles
Most recent articles on Panobinostat Most cited articles on Panobinostat Review articles on Panobinostat Articles on Panobinostat in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Panobinostat Images of Panobinostat Photos of Panobinostat Podcasts & MP3s on Panobinostat Videos on Panobinostat
Evidence Based Medicine
Cochrane Collaboration on Panobinostat Bandolier on Panobinostat TRIP on Panobinostat
Clinical Trials
Ongoing Trials on Panobinostat at Clinical Trials.gov Trial results on Panobinostat Clinical Trials on Panobinostat at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Panobinostat NICE Guidance on Panobinostat NHS PRODIGY Guidance FDA on Panobinostat CDC on Panobinostat
Books
Books on Panobinostat
News
Panobinostat in the news Be alerted to news on Panobinostat News trends on Panobinostat
Commentary
Blogs on Panobinostat
Definitions
Definitions of Panobinostat
Patient Resources / Community
Patient resources on Panobinostat Discussion groups on Panobinostat Patient Handouts on Panobinostat Directions to Hospitals Treating Panobinostat Risk calculators and risk factors for Panobinostat
Healthcare Provider Resources
Symptoms of Panobinostat Causes & Risk Factors for Panobinostat Diagnostic studies for Panobinostat Treatment of Panobinostat
Continuing Medical Education (CME)
CME Programs on Panobinostat
International
Panobinostat en Espanol Panobinostat en Francais
Business
Panobinostat in the Marketplace Patents on Panobinostat
Experimental / Informatics
List of terms related to Panobinostat

Panobinostat
Clinical data
Trade names	Farydak
Routes of; administration	Oral
ATC code	L01XX42 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	21%
Protein binding	90%
Metabolism	CYP3A (40%), CYP2D6, CYP2C19
Elimination half-life	37 hours
Excretion	Fecal (44–77%), renal (29–51%)
Identifiers
	IUPAC name (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide;
CAS Number	404950-80-7 ;
PubChem CID	6918837;
ChemSpider	5294028 ;
UNII	9647FM7Y3Z;
KEGG	D10019 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H23N3O2
Molar mass	349.42622 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(NO)\C=C\c1ccc(cc1)CNCCc3c2ccccc2nc3C;
	InChI InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+ ; Key:FPOHNWQLNRZRFC-ZHACJKMWSA-N ;
(what is this?) (verify)

VisualWikitext

Revision as of 15:12, 8 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Panobinostat (LBH-589, trade name Farydak) is a drug developed by Novartis for the treatment of various cancers. It is a hydroxamic acid^[2] and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).^[3]

On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent."^[4] after clinical trials.^[5]

Clinical trials

As of August 2012^[update], it is being tested against Hodgkin's Lymphoma, cutaneous T cell lymphoma (CTCL)^[6] and other types of malignant disease in Phase III clinical trials, against myelodysplastic syndromes, breast cancer and prostate cancer in Phase II trials, and against chronic myelomonocytic leukemia (CMML) in a Phase I trial.^[7]^[8]

As of 2014^[update] Panobinostat is being used in a Phase I/II clinical trial that aims at curing AIDS in patients on highly active antiretroviral therapy (HAART). In this technique, panobinostat is used to drive the HIV DNA out of the patient's DNA, in the expectation that the patient's immune system in combination with HAART will destroy it.^[9]^[10] ^[11]

Preclinical studies

Panobinostat has been found to synergistically act with sirolimus to kill pancreatic cancer cells in the laboratory in a Mayo Clinic study. In the study, investigators found that this combination destroyed up to 65 percent of cultured pancreatic tumor cells. The finding is significant because the three cell lines studied were all resistant to the effects of chemotherapy – as are many pancreatic tumors.^[12]

Panobinostat has also been found to significantly increase in vitro the survival of motor neuron (SMN) protein levels in cells of patients suffering from spinal muscular atrophy.^[13]

Panobinostat was able to selectively target triple negative breast cancer (TNBC) cells by inducing hyperacetylation and cell cycle arrest at the G2-M DNA damage checkpoint; partially reversing the morphological changes characteristic of breast cancer cells.^[14]

Panobinostat, along with other HDAC inhibitors, is also being studied for potential to induce virus HIV-1 expression in latently infected cells and disrupt latency. These resting cells are not recognized by the immune system as harboring the virus and do not respond to antiretroviral drugs.^[15]

Mechanism of action

Panobinostat inhibits multiple histone deacetylase enzymes, a mechanism leading to apoptosis of malignant cells via multiple pathways.^[2]

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 Panobinostat Package Insert
↑ ^2.0 ^2.1 Revill, P; Mealy, N; Serradell, N; Bolos, J; Rosa, E (2007). "Panobinostat". Drugs of the Future. 32 (4): 315. doi:10.1358/dof.2007.032.04.1094476. ISSN 0377-8282.
↑ Table 3: Select epigenetic inhibitors in various stages of development from Template:Cite doi
↑ FDA.gov announcement about accelerated approval of panobinostat (Farydak)
↑ Panobinostat chemotherapy regimen for multiple myeloma (MM wiki)
↑ Clinical trial number NCT00425555 for "Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma" at ClinicalTrials.gov
↑ ClinicalTrials.gov: LBH-589
↑ Prince, HM; M Bishton (2009). "Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma". Hematology Meeting Reports. Parkville, Australia: Peter MacCallum Cancer Centre and University of Melbourne. 3 (1): 33–38.
↑ Simons, J (27 April 2013). "Scientists on brink of HIV cure". The Telegraph.
↑ Clinical trial number NCT01680094 for "Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART (CLEAR)" at ClinicalTrials.gov
↑ Template:Cite doi
↑ Mayo Clinic Researchers Formulate Treatment Combination Lethal To Pancreatic Cancer Cells
↑ Garbes, L; Riessland, M; Hölker, I; Heller, R; Hauke, J; Tränkle, Ch; Coras, R; Blümcke, I; Hahnen, E; Wirth, B (2009). "LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate". Human Molecular Genetics. 18 (19): 3645–3658. doi:10.1093/hmg/ddp313. PMID 19584083.
↑ Tate, CR; Rhodes, LV; Segar, HC; Driver, JL; Pounder, FN; Burow, ME; Collins-Burow, BM (2012). "Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat". Breast Cancer Research. 14 (3).
↑ TA Rasmussen, et al. Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. Human Vaccines & Immunotherapeutics 9:5, 1-9, May 2013.

Template:Intracellular chemotherapeutic agents

[PackageInsert-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 Panobinostat Package Insert

[Revill2007-2] 2.0 ^2.1 Revill, P; Mealy, N; Serradell, N; Bolos, J; Rosa, E (2007). "Panobinostat". Drugs of the Future. 32 (4): 315. doi:10.1358/dof.2007.032.04.1094476. ISSN 0377-8282.

[NBT2010-3] Table 3: Select epigenetic inhibitors in various stages of development from Template:Cite doi

[4] FDA.gov announcement about accelerated approval of panobinostat (Farydak)

[5] Panobinostat chemotherapy regimen for multiple myeloma (MM wiki)

[6] Clinical trial number NCT00425555 for "Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma" at ClinicalTrials.gov

[7] ClinicalTrials.gov: LBH-589

[pan-8] Prince, HM; M Bishton (2009). "Panobinostat (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma". Hematology Meeting Reports. Parkville, Australia: Peter MacCallum Cancer Centre and University of Melbourne. 3 (1): 33–38.

[Jake_Wallis_Simons2013-9] Simons, J (27 April 2013). "Scientists on brink of HIV cure". The Telegraph.

[10] Clinical trial number NCT01680094 for "Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART (CLEAR)" at ClinicalTrials.gov

[11] Template:Cite doi

[12] Mayo Clinic Researchers Formulate Treatment Combination Lethal To Pancreatic Cancer Cells

[13] Garbes, L; Riessland, M; Hölker, I; Heller, R; Hauke, J; Tränkle, Ch; Coras, R; Blümcke, I; Hahnen, E; Wirth, B (2009). "LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate". Human Molecular Genetics. 18 (19): 3645–3658. doi:10.1093/hmg/ddp313. PMID 19584083.

[14] Tate, CR; Rhodes, LV; Segar, HC; Driver, JL; Pounder, FN; Burow, ME; Collins-Burow, BM (2012). "Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat". Breast Cancer Research. 14 (3).

[15] TA Rasmussen, et al. Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. Human Vaccines & Immunotherapeutics 9:5, 1-9, May 2013.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

@@ Line 4: / Line 4: @@
 | verifiedrevid = 455315413
 | IUPAC_name = (2''E'')-''N''-hydroxy-3-[4-({[2-(2-methyl-1''H''-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
-| image = Panobinostat structure.svg
+| image =Panobinostat structure.png
 <!--Clinical data-->
 | tradename = Farydak

Clinical data

Trade names	Farydak
Routes of administration	Oral
ATC code	L01XX42 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	21%^[1]
Protein binding	90%^[1]
Metabolism	CYP3A (40%), CYP2D6, CYP2C19^[1]
Elimination half-life	37 hours^[1]
Excretion	Fecal (44–77%), renal (29–51%)^[1]
Identifiers
IUPAC name (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
CAS Number	404950-80-7^Y
PubChem CID	6918837
ChemSpider	5294028^N
UNII	9647FM7Y3Z
KEGG	D10019^N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₁H₂₃N₃O₂
Molar mass	349.42622 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(NO)\C=C\c1ccc(cc1)CNCCc3c2ccccc2nc3C
InChI InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+^N Key:FPOHNWQLNRZRFC-ZHACJKMWSA-N^N
^NY (what is this?) (verify)